Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
Last trade$0.5027
Day change-$0.035 (-6.51%)
Day range$0.495 – $0.567
Volume5,856,164
Market cap$158M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$159.17M
Price / earnings
—
Price / book
0.88×
Price / sales
2.73×
EV / sales
-0.02×
EV / EBITDA
0.01×
Profitability
Earnings per share
-$0.36
Return on assets
-49.04%
Return on equity
-59.27%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.87×
Quick ratio
5.87×
Cash ratio
5.16×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$109.66M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IVVD, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$14.29M
$13.74M
$17.21M
$13.13M
$11.79M
$11.3M
$13.82M
$9.3M
Cost of revenue
$1.27M
$1.03M
$1.14M
$1.09M
$685K
$834K
$724K
$806K
Gross profit
$13.01M
$12.71M
$16.07M
$12.04M
$11.1M
$10.47M
$13.1M
$8.49M
Selling, general and administrative
$29.47M
$25.12M
$18.57M
$15.02M
$16.59M
$16.75M
$14.42M
$12.96M
Research and development
$29.37M
$30.73M
$10.05M
$8.05M
$9.57M
$10.64M
$17.91M
$57.85M
Total operating expenses
$58.83M
$55.85M
$28.62M
$23.06M
$26.16M
$27.39M
$32.33M
$70.81M
Operating income
-$45.82M
-$43.14M
-$12.56M
-$11.02M
-$15.06M
-$16.92M
-$19.23M
-$62.31M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$44.39M
-$41.4M
-$11.07M
-$10.47M
-$14.66M
-$16.29M
-$18.44M
-$60.74M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$44.39M
-$41.4M
-$11.07M
-$10.47M
-$14.66M
-$16.29M
-$18.44M
-$60.74M
Net income attributable to common shareholders
-$44.39M
-$41.4M
-$11.07M
-$10.47M
-$14.66M
-$16.29M
-$18.44M
-$60.74M
EBITDA
-$45.64M
-$42.97M
-$12.41M
-$10.87M
-$14.91M
-$16.62M
-$18.15M
-$62.18M
Basic earnings per share
-$0.14
-$0.13
-$0.04
-$0.06
-$0.12
-$0.14
-$0.15
-$0.51
Diluted earnings per share
-$0.14
-$0.13
-$0.04
-$0.06
-$0.12
-$0.14
-$0.15
-$0.51
Recent news
Company coverage with links to the original publishers.
Invivyd, Inc. (IVVD) reported a quarterly loss of $0.10 per share, beating the consensus estimate of $0.11 loss, representing a 9.09% earnings surprise. However, the company missed revenue expectations with $15.45 million versus the consensus estimate, down 2.84%. The stock has declined 76.4% year-to-date and carries a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.
Milestone Pharmaceuticals reported a Q3 loss of $0.18 per share, beating consensus estimates of $0.20 loss, with a 10% earnings surprise. The company posted $2.96 million in revenues, significantly surpassing estimates by 161.52%, compared to zero revenues a year ago. However, the stock has declined 67.6% year-to-date and carries a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions.
TELA Bio exceeded EPS expectations with a loss of $0.13 per share versus consensus estimate of $0.19, representing a 31.58% earnings surprise. However, revenues declined to $18.96 million from $20.69 million year-over-year. The stock has underperformed the market by 26.7% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Invivyd, Inc. announced a partnership with Olympic skier Lindsey Vonn to launch a national multimedia educational campaign in spring 2026 focused on teaching Americans about antibodies and disease prevention. Vonn will serve as the public-facing spokesperson for the initiative, leveraging her credibility and comeback story to advance public understanding of antibody science and immune system health.
Invivyd reported Q4 2025 PEMGARDA net product revenue of $17.2 million, representing 25% year-over-year growth and 31% quarter-over-quarter growth. The company announced a strong balance sheet with $226.7 million in cash after raising over $200 million in 2H 2025. Key developments include initiation of the DECLARATION Phase 3 pivotal trial for COVID vaccine-alternative VYD2311 with top-line data expected mid-2026, FDA Fast Track designation for VYD2311, and nomination of potential best-in-class RSV antibody VBY329 for preclinical development.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.